Autres langues Aelis Farma

Actions

AELIS

FR0014007ZB4

Marché Fermé - Euronext Paris Autres places de cotation 09:00:17 16/07/2024			Varia. 5j.	Varia. 1 janv.
12 ^EUR	+0,84 %		-1,64 %	-8,40 %

19/04	Les nuages s'amoncellent sur les marchés
19/04	En Direct des Marchés : Schneider, L'Oréal, EssilorLuxottica, Sodexo, Believe, TSMC, Netflix...

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Aelis Farma : Share buyback program description	24/06
Aelis Farma: Availability of the Description of the Share Buyback Program	24/06
Results of Aelis Farma Combined General Meeting of June 4, 2024	04/06
Aelis Farma : Availability of documents for the General meeting on June 4, 2024	14/05
Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures	14/05
Aelis Farma: Availability of the 2023 Universal Registration Document	25/04
Bolsa de Madrid: Las nubes se ciernen sobre los mercados	19/04
Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	18/04
Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	18/04
Bolsa de Madrid: Después de Semana Santa, algo va mal	03/04
Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook	02/04
Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Aelis Farma Appoints Chief Corporate Development Officer	18/01
Aelis Farma Announces the Appointment of Arsène Guekam as Chief Corporate Development Officer	17/01
Aelis Farma Announces Completion of Patient Randomization for Phase 2B Study with Aef0117 for the Treatment of Cannabis Addiction	09/01
Bolsa de Madrid: ¿El Nasdaq no lo para nadie?	08/11
Aelis Farma Announces Positive Results of Non-Clinical Studies Required by Regulatory Agencies to Enter Its First Cb1-SSI, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder	07/11
Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2023	25/09/23
Bolsa de Madrid: La renta variable se queda sin combustible	25/09/23
Aelis Farma : le DG et cofondateur récompensé par ses pairs	29/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aelis Farma

Actions

AELIS

FR0014007ZB4

Autres langues

Filtres